SUBSCRIBE
SUBSCRIBE

Neurodegenerative disease

The Philadelphia skyline
Alzheimer’s disease
New Leqembi Data Illuminate Longer-Term Effects, Tau Reduction
Eisai presented a plethora of data on the drug at the Alzheimer’s Association International Conference, including a study showing the consequences of pausing treatment.
July 31, 2024
 · 
5 min read
 · 
Kate Goodwin
A brain hovers over a hand against a yellow-striped background
Neuroscience
5 Neuro Data Readouts to Watch in the Second Half of 2024
After a busy first half of 2024, several companies are expecting key data readouts in the neuropsychiatric and neurodegenerative disease spaces during the next six months.
July 15, 2024
 · 
6 min read
 · 
Heather McKenzie
A scientist studies genes on a computer screen
Parkinson’s disease
Breaking the Cycle of Inflammation in Parkinson’s Disease
Halia Therapeutics, NodThera and Gain Therapeutics target neuroinflammatory processes in hopes of modifying the course of Parkinson’s progression.
July 15, 2024
 · 
4 min read
 · 
Jill Drachenberg
Load More
PRESS RELEASES
Press Releases
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
May 14, 2026
 · 
8 min read
Press Releases
Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027
May 12, 2026
 · 
5 min read
Press Releases
NeuroVision Acquires Durin Life Sciences to Advance Earlier Detection and Management of Neurodegenerative Disease
May 12, 2026
 · 
2 min read
Press Releases
Arbor Biotechnologies Achieves Unprecedented Precise In Vivo Reverse Transcriptase Editing in the Brain Using a Single AAV Vector, Opening a New Path to Treatments for Neurological Diseases
May 12, 2026
 · 
3 min read
Press Releases
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
May 12, 2026
 · 
14 min read
Press Releases
GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments
May 11, 2026
 · 
3 min read
Press Releases
Cellular Intelligence, an AI-native TechBio, Enters Agreement with Novo Nordisk to Advance Clinical-Stage Parkinson’s Cell Therapy
May 11, 2026
 · 
4 min read
Press Releases
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
May 8, 2026
 · 
14 min read
Press Releases
Sangrail Biologics Launches with Mission of Restoring Life’s Blueprint for Children with Rare Genetic Diseases
May 5, 2026
 · 
7 min read
Press Releases
Clene to Present at Upcoming May 2026 Conferences
May 5, 2026
 · 
1 min read
Press Releases
MMI’s Symani Surgical System Treats First Alzheimer’s Patient in Groundbreaking REMIND Study
May 4, 2026
 · 
5 min read
Press Releases
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
May 4, 2026
 · 
7 min read
Press Releases
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer’s Disease
April 30, 2026
 · 
6 min read
Press Releases
AC Immune First Quarter 2026 Financial and Corporate Updates
April 30, 2026
 · 
11 min read
Press Releases
GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026
April 29, 2026
 · 
2 min read
Press Releases
CIRM Awards AcuraStem $7.5 Million in Grant Funding to Advance AS-241 Toward a First-in-Human Trial for ALS and FTD
April 29, 2026
 · 
3 min read
Press Releases
VectorY Therapeutics Receives U.K. MHRA Authorization and EMA Approval to Initiate Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People Living with Amyotrophic Lateral Sclerosis (ALS)
April 28, 2026
 · 
3 min read
Press Releases
Annovis Publishes Phase 2/3 Alzheimer’s Trial Results in Nature Portfolio
April 28, 2026
 · 
4 min read
Press Releases
Arcera Life Sciences and Fosun Pharma launch long-term collaboration framework
April 28, 2026
 · 
5 min read
Press Releases
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
April 27, 2026
 · 
4 min read
Load More